OxSonics Therapeutics
Oxford
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time. The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics is based in Oxford in the UK. For more information please visit: www.oxsonics.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $32.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2020)
- Website: oxsonics.com
- Phone: +4401865784777
Industries & Categories
Biotechnology, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/oxsonics-therapeutics-35208 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.